Projects › FORECAST
Central question 9: How can we predict and outrun resistance before it appears?
Why
Second-line treatment of GIST is changing. Bezuclastinib with sunitinib, velzatinib (IDRX-42), NB003 and ripretinib each cover a different set of resistance mutations, and each leaves a different set behind. What grows after these drugs, lesion by lesion, decides what the third line can still do. Nobody has looked at this systematically, because the trials that test the drugs end at progression.
Aims
Questions
- Which resistance mutations appear after each of the new second-line drugs?
- How heterogeneous is resistance between lesions in the same patient?
- How do patients fare on the treatment lines that follow, depending on what resistance they carry?
What is collected
- Mutation at diagnosis and at each progression, from tissue or ctDNA
- CT scans at progression, read lesion by lesion
- Every treatment line after the second-line drug, with response and duration
- Patients from the trials of these drugs and from routine care
How
FORECAST builds on the tools of PATHFINDERS: lesion tracking on serial CT scans, ctDNA and long-read sequencing of KIT, brought together in one interface. Patients enter at progression on a second-line drug; their resistance profile and every later line are followed in the registry. The sample size depends on how many patients the trials and the participating centers can contribute; the first analysis is descriptive.
Sites
Activated sites and current status: to be added by the project leads.
What comes next
The resistance profiles define the cohorts of the resistance template of the platform trial: a protocol that treats resistance before it arises, rather than after.